Point-of-Care Multiplex for Adult Patients With Severe Community-acquired Pneumonia

Clinical Impact on Point-of-Care Multiplex Polymerase Chain Reaction (PCR) Testing for Critically Ill Adult Patients With Community-acquired Pneumonia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04835818

Enrollment

Registered

2021-04-08

Start date

2019-05-02

Completion date

2022-05-31

Last updated

2021-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired Pneumonia, Critical Illness

Keywords

Community-acquired Pneumonia, Critical Illness, Point-of-care

Brief summary

Clinical Impact on Point-of-Care Multiplex PCR Testing for Critically Ill Adult Patients With Community-acquired Pneumonia - A cluster randomization study in ICU units within one medical center.

Detailed description

Point-of-Care Multiplex PCR Testing could narrow down the pathogens causing severe community-acquired pneumonia(CAP). Our hypothesis is that the result of Point-of-Care Multiplex PCR Testing could help primary physician to reduce antibiotics use.

Interventions

DIAGNOSTIC_TESTProvide the panel report to the primary care physician

Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (age \>20 y/o) * ICU admission for acute respiratory failure due to community-acquired pneumonia by clinical diagnosis * Treatment with endotracheal Intubation

Exclusion criteria

* Aspiration pneumonia (including witnessed aspiration and chronic bedridden status) * Nosocomial infection

Design outcomes

Primary

Measure	Time frame	Description
Intravenous antibiotic-free day within 14 days	up to 14 days	days without intravenous antibiotics within 14 days

Secondary

Measure	Time frame	Description
ICU stay	up to 21 days	days of stay in ICU
Antibiotic-free day within 21 days	21 days	days without antibiotics within 21 days
Intravenous antibiotic-free day within 21 days	up to 21 days	days without intravenous antibiotics within 21 days
Ventilator-free day within 28 days	up to 28 days	days without intravenous antibiotics within 28 days

Countries

Taiwan

Contacts

Primary ContactYu-Chung Chuang, MD. PhD

weischuang@gmail.com886-2-23123456

Backup ContactYu-Chung Chuang, MD. PhD

886-972652532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026